Phase II Data Demonstrate Abbott's Most Advanced NNR Candidate ABT-089
Shows Strong Safety, Tolerability And Efficacy in Adults With ADHD
ABBOTT PARK, Ill., May 7 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) and other leading scientists will present new Phase II data showing that ABT-089, a selective neuronal nicotinic receptor (NNR) agonist, is a potentially effective and safe treatment for adults with Attention-Deficit Hyperactivity Disorder (ADHD). The studies are being presented today at the American Psychiatric Association (http://www.psych.org/) 161st Annual Meeting in Washington, D.C.
Phase II study results show that ABT-089 appears to significantly improve the core symptoms of ADHD, improve quality-of-life and work effectiveness, and reduce overall work impairment in adults with ADHD. Data also revealed that ABT-089 appears to be generally well tolerated with no significant negative effects on sleep, appetite or vital signs (heart rate and blood pressure).
ADHD, an ailment historically associated with childhood, persists into adulthood in more than two-thirds of cases. While medical treatment can improve the symptoms of ADHD, currently approved treatments often cause undesirable side effects, including increases in heart rate and blood pressure.
ABT-089 appears to exhibit an improved profile compared to current
treatments by improving the core and associated symptoms of ADHD without
clinically significant side effects. The compound targets specific types of
NNRs found on nerve cells in the central nervous system. NNRs, also known
as neuronal nicotinic acetylcholine receptors (nAChRs), modulate the
release of several important neurotransmitters, such
Copyright©2008 PR Newswire.
All rights reserved